Patent Application
20240024402
The present invention relates to a composition for improving insulin sensitivity, comprising a Gentiana trillora Pallas extract. More particularly, the present invention relates to a composition characterized by improving insulin sensitivity by reducing the expression of ITIH1 (Inter-alpha Trypsin Inhibitor Heavy chain 1).
In normal cases, the body maintains homeostasis by regulating blood glucose concentration. However, in metabolic diseases and diseases accompanied by insulin resistance, blood sugar is excessively increased, and when such high blood sugar persists, tissue damage and functional disorders are caused.
Insulin resistance is a decrease in sensitivity to insulin compared to the normal standards, and refers to a case in which an increase in insulin in muscle and adipose tissue is not detected or the action of insulin does not occur effectively even if it is detected. In this case, the balance of cell metabolism and metabolism cannot be effectively maintained because blood sugar cannot be lowered.
In order to improve insulin sensitivity, a method of increasing the secretion of insulin itself in the beta (B) cells of the pancreas or amplifying the signal transmitted by the insulin receptor binding to insulin in the metabolic pathway is mainly considered, but research on how to control hyperglycemia by regulating the activity of the protein itself involved in hyperglycemia based on the biological mechanism that causes hyperglycemia is insufficient.
ITIH1 (Inter-alpha Trypsin Inhibitor Heavy chain 1) is a protein produced in hepatocytes and secreted into the blood, and its intracellular concentration and secretion amount are increased by glucose stimulation (Science Translational Medicine, Vol. 11, Issue 513, eaan4735, 2019). Specifically, the increase in ITIH1 is achieved by a decrease in G13, a type of G protein, and an increase in the expression level of OGT (O-GlcNAc transferase) enzyme in hyperglycemia. In a hyperglycemic environment, OGT induces O-GlcNAcylation modification on the serine residue of ITIH1, which increases the stability of ITIH1. As a result, when the concentration of ITIH1 is increased, ITIH1 binds to hyaluronic acid and reduces insulin sensitivity in muscle and adipocytes.
On the other hand, Gentiana trillora Pallas is a perennial plant of the Gentiana scabra family, and its flowers bloom in sky blue in July and August, the rhizome is thick, the main stem stands straight, and there is no hair. It is distributed in Korea, Manchuria, Japan, and eastern Siberia. It is similar to Gentiana scabra, but it is different from Gentiana scabra in that there are no projections on the stem and the main veins on the lower surface of leaves, the flowers do not bloom in full bloom, and the forked pieces of the corolla are not bent. The roots that are dug up and dried in the fall are used for indigestion, cholecystitis, jaundice, headache, encephalitis, cystitis, urethritis, and the like, but nothing is known about an effect of Gentiana trillora Pallas on improving insulin sensitivity.
In this regard, the inventors of the present invention found that a Gentiana trillora Pallas extract can improve insulin sensitivity by inhibiting the expression of ITIH1. Based on the above, the present inventors completed the present invention.
An object of the present invention is to provide a composition capable of improving insulin sensitivity by reducing the expression of ITIH1, comprising a Gentiana trillora Pallas extract.
In order to achieve the above object, the present invention provides a composition for improving insulin sensitivity, comprising a Gentiana trillora Pallas extract.
The composition may be a pharmaceutical composition, a food composition, or an animal feed composition.
In one embodiment, the composition has an effect of increasing insulin sensitivity and reducing insulin resistance.
In one embodiment, the composition may be for the prevention, treatment or improvement of at least one disease selected from the group consisting of diabetes, diabetic complications, impaired glucose tolerance, and insulin resistance syndrome.
In one embodiment, the diabetic complications may be at least one disease selected from the group consisting of diabetic retinopathy, diabetic cataract, diabetic nephropathy, and diabetic neuropathy.
In one embodiment, the insulin resistance syndrome may be at least one disease selected from the group consisting of obesity, hypertension, arteriosclerosis, hyperlipidemia, hyperinsulinemia, non-alcoholic fatty liver, and type 2 diabetes caused by insulin resistance.
In one embodiment, the Gentiana trillora Pallas extract may be a Gentiana trillora Pallas whole plant extract, a root extract, a leaf extract, a flower extract or a stem extract, and preferably, it may be a Gentiana triflora Pallas whole plant extract or a Gentiana trillora Pallas root extract.
In one embodiment, the Gentiana trillora Pallas extract may reduce the expression of itih1 (Inter-alpha Trypsin Inhibitor Heavy chain 1) mRNA or ITIH1 protein.
In one embodiment, the Gentiana trillora Pallas extract may reduce the expression of ogt (O-GlcNAc Transferase) mRNA.
In one embodiment, the extract may be extracted with a solvent selected from the group consisting of water, C1 to C6 alcohol, and mixed solvents thereof, and may be a methanol extract.
In one embodiment, the extract may be extracted with an aqueous solution of methanol 10 times the weight of Gentiana trillora Pallas, but is not limited thereto.
In one embodiment, the extract may be ultrasonically extracted at 40 to 50° C., but is not limited thereto.
The composition comprising a Gentiana trillora Pallas extract according to the present invention has an effect of improving insulin sensitivity by reducing the expression of ITIH1. Therefore, the composition of the present invention can be effectively used as a therapeutic agent for diabetes, diabetic complications, impaired glucose tolerance, insulin resistance syndrome and the like.
Hereinafter, with reference to the accompanying drawings, embodiments and examples of the present invention will be described in detail so that those of ordinary skill in the art to which the present invention belongs can easily carry out. However, the present invention may be implemented in various forms and is not limited to the embodiments and examples described herein.
Throughout the present specification, when a certain part “includes” a certain component, it means that other components may be further included, rather than excluding other components, unless otherwise stated.
The present invention relates to a composition for improving insulin sensitivity, comprising a Gentiana trillora Pallas extract.
The Gentiana triflora Pallas extract of the present invention may be a Gentiana trillora Pallas whole plant extract, a root extract, a leaf extract, a flower extract or a stem extract. The whole plant refers to the entire plant with flowers, roots, leaves, stems, and the like.
The composition has the efficacy of inhibiting the expression of ITIH1 (Inter-alpha Trypsin Inhibitor Heavy chain 1). ITIH1 is a protein produced in hepatocytes and secreted into the blood, and its intracellular concentration and secretion amount are increased by glucose stimulation. It binds to hyaluronic acid and reduces insulin sensitivity in muscle and adipocytes.
In addition, the composition inhibits the expression of OGT (O-GlcNAc transferase). OGT increases the stability and concentration of ITIH1 by causing O-GlcNAcylation modifications to serine residues in the ITIH1 protein. Therefore, the composition of the present invention has an effect of improving insulin sensitivity by reducing the expression of ITIH1 and OGT.
The effect of improving insulin sensitivity refers to an increase in insulin sensitivity and a decrease in insulin resistance. Insulin sensitivity refers to the degree of response to insulin. A decrease in insulin sensitivity, i.e., insulin resistance, means that cells cannot effectively bum glucose due to a decrease in the response to insulin compared to the normal standards, resulting in a decrease in the function of insulin to lower blood sugar.
As a method for extracting the Gentiana trillora Pallas extract of the present invention, conventional methods in the art such as stirring extraction, filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction can be used.
The pharmaceutical composition of the present invention can be parenterally administered or orally administered depending on the desired method, and the range of dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease and the like. In addition, the therapeutically effective amount of the composition may vary depending on the administration method, the target site, and the condition of the patient, and when used in the human body, the dosage should be determined in an appropriate amount in consideration of safety and efficiency.
The pharmaceutical composition of the present invention may be formulated and used in any form suitable for pharmaceutical preparations, including oral formulations such as powders, granules, tablets, soft or hard capsules, suspensions, emulsions, syrups, aerosols and the like, external formulations for skin such as ointments, creams and the like, suppositories, injections and sterile injection solutions and the like, respectively, according to conventional methods.
Excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, diluents, and the like commonly used for the formulation may be further included. For example, excipients that may be included in the pharmaceutical composition of the present invention may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, methyl hydroxy benzoate, propyl hydroxy benzoate, talc, magnesium stearate and mineral oil and the like, but are not limited thereto. In addition to simple excipients, lubricants such as magnesium stearate and talc may be also used. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. Witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, and the like may be used as a base for the suppository.
The food composition of the present invention may be a health functional food. The “health functional food” refers to a food manufactured and processed using raw materials or ingredients having useful functionality for the human body, and “functionality” refers to regulating nutrients for the structure and function of the human body or ingesting nutrients for the purpose of obtaining useful effects for health purposes such as physiological functions and the like.
The food composition can be manufactured and processed into health functional foods in the form of tea bags, leached tea, health drinks, and the like, and can be also processed into other breads, confectionaries, ice creams, noodles, and the like. In addition, the food composition may be a health supplement food or a food additive, and whether or not it is suitable as a “food additive” is determined by the standards and criteria for the relevant item in accordance with the General Rules of the Food Additives Code and General Test Methods and the like approved by the Ministry of Food and Drug Safety, unless otherwise specified.
Hereinafter, the present invention will be described in more detail through the examples, but the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
Preparation of Gentiana triflora Pallas Extract Ultrasonic extraction was performed at 45° C. by adding 10 folds of 99.9% methanol to 100 g of dried powder for each part of the whole plant and root of Gentiana triflora Pallas purchased from the Korea Plant Extract Bank. The process of operating the ultrasonic extractor for 15 minutes and stopping for 2 hours was defined as one time, and the process was performed a total of 30 times for 3 days to obtain an extraction solution. This extraction solution was filtered, and then it was concentrated under reduced pressure at 45° C. to obtain a powder, and the following experiments were conducted.
Confirmation of Cell Cytotoxicity of Gentiana triflora Pallas Extract
In order to confirm the cell cytotoxicity of the Gentiana triflora Pallas extract, MTT assay was performed as follows. the HepG2 cells were dispensed to 4×104 cells/ml in a 96 well plate and then cultured for 24 hours to perform attachment and stabilization. After culturing for 24 hours, the Gentiana triflora Pallas whole plant, root extract was diluted in the culture solution to a final extraction concentration of 10 μg/ml, supplied to the cell line, and cultured for 24 hours. After 24 hours, the medium was removed, and 100 μl of the MTT solution (0.5 mg/ml in PBS) was dispensed and reacted for 30 minutes to reduce MTT in a carbon dioxide humidified incubator (CO2 Incubator) at 37° C., 5% conditions. Formazan crystals generated in each well were dissolved in 200 μl of DMSO (dimethyl sulfoxide). The absorbance of each sample was measured at 570 nm using a multimode plate reader (Varioskan LUX multimode plate reader, Thermo Scientific, Vantaa, Finland), and cell viability was confirmed using the untreated group as a negative control, and the results are shown in
As shown in
Confirmation of Increased Expression of Itihl mRNA Under High Concentration Glucose Conditions
It is known that ITIH1 binds to hyaluronic acid, deposits in hepatocytes, and reduces the insulin sensitivity of cells. The evaluation method for ITIH1 inhibitory efficacy was confirmed as follows.
Primary cells isolated from cell lines or animals were cultured in a cell culture medium containing low concentration (5 mM) and high concentration (25 mM) glucose for 24 hours, respectively. At this time, it was confirmed that the O-GlcNAc modification (CTD 110.6 clone) increased and the expression of ITIH1 increased in the medium containing high concentration of glucose.
In addition, the HepG2 cells were cultured in a cell culture medium containing glucose, fructose, methylglyoxal (MGO), glyoxal (GO), glyceraldehyde 3-phosphate (G3P), glyceraldehyde, and glycolaldehyde for 24 hours, respectively, and the expression level of itih1 mRNA was measured and shown in
As shown in
Confirmation of Effect of Gentiana triflora Pallas Extract on Inhibiting Itihl mRNA Expression
After treating the HepG2 cells with the Gentiana triflora Pallas extract, real-time polymerase chain reaction (quantitative PCR, qPCR) was performed as follows in order to confirm an effect of inhibiting itih1 mRNA expression.
The cells were cultured in a cell culture medium containing high concentration (25 mM) glucose for 24 hours, and then the Gentiana triflora Pallas whole plant, root extract was diluted in the culture solution to a final extraction concentration of 10 μg/ml, supplied to the cell line, and cultured for 24 hours. After 24 hours, the medium was removed and washed with PBS, and then the attached cells were scraped off with a scraper and collected in a centrifuge. Total RNA was extracted from the cells using a miRNA extraction kit (mirVana miRNA Isolation Kit), and cDNA was synthesized using a ReverTra Ace qPCR RT Master Mix with gDNA Remover, and then it was used as a template DNA to confirm the transcript expression level. In order to confirm the expression of itih1 mRNA, primer pairs of itih1-qper1 and itih1-qper2 were used, and qPCR reactions were performed using primer pairs of gapdh-qper1 and gapdh-qper2 as a reference gene, respectively. It was confirmed whether or not the gene sequence was amplified at the transcript level. The sequences of each primer pair are shown in Table 1 below.
As confirmed in
Confirmation of Effect of Gentiana triflora Pallas Extract on Inhibiting ITIH1 Protein Expression
In the cells obtained in Example 3, the expression of ITIH1 protein was confirmed by Western blotting. Specifically, the cell lysates were obtained by lysing the cells with a cell lysis buffer (RIPA lysis buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS), 120 mM, Protease Inhibitor Cocktail (AEBSF, Aprotinin, Bestatin, E64, Leupeptin, and Pepstatin A), Phosphatase Inhibitor Cocktail (sodium fluoride, sodium pyrophosphate, β-glycerophosphate, and sodium orthovanadate)), and the cell lysates were mixed with a sample buffer (60 mM Tris-HCl (pH 6.8), 25% glycerol, 0.1% bromophenol blue, 2% SDS, 2% mercapto ethanol) and cultured for 10 minutes on a heating block at 100° C. The supernatant was collected by centrifugation at 13,000 rpm, 4° C. for 5 minutes, and each sample was loaded into an SDS PAGE gel (12%) and electrophoresed at 120 V. The entire protein separated in the SDS PAGE gel was transferred to the NC membrane, and then ITIH1 protein expression was confirmed using an antibody against ITIH1 (matured form) and β-actin, and the results are shown in
Gentiana triflora Pallas root 1 μg/ml
Gentiana triflora Pallas root 10 μg/ml
As shown in
As a result, it can be seen that the Gentiana triflora Pallas extract has an effect of improving insulin sensitivity and an effect of treating diseases related to insulin resistance by excellently inhibiting both mRNA expression and protein expression of ITIH1, which lowers insulin sensitivity in a hyperglycemic environment.
Confirmation of Increased Expression of Ogt mRNA Under High Concentration Glucose Conditions
It is known that the increase in OGT (O-GlcNAc transferase) due to the decrease in G13 (G protein alpha-13) in hyperglycemic conditions increases the stability of ITIH1, increasing the intracellular concentration and secretion amount of ITIH1. The evaluation method for ogt mRNA inhibitory efficacy was confirmed as follows.
The HepG2 cells were cultured in a cell culture medium containing glucose, fructose, methylglyoxal (MGO), glyoxal (GO), glyceraldehyde 3-phosphate (G3P), glyceraldehyde, and glycolaldehyde for 24 hours, respectively, and the expression level of ogt mRNA was measured and shown in
As shown in
Confirmation of Effect of Gentiana triflora Pallas Extract on Inhibiting Ogt mRNA Expression
After treating HepG2 cells with the Gentiana triflora Pallas extract, real-time polymerase chain reaction (quantitative PCR, qPCR) was performed as follows in order to confirm an effect of inhibiting ogt mRNA expression.
The HepG2 cells were cultured in a cell culture medium containing high concentration (25 mM) glucose for 24 hours, and then 500 μM MGO was induced for 1 hour. After treatment, the Gentiana triflora Pallas root extract was diluted in the culture solution to a final extraction concentration of 10 μg/ml, supplied to the cell line, and cultured for 24 hours. After 24 hours, the medium was removed and washed with PBS, and then the attached cells were scraped off with a scraper and collected in a centrifuge. Total RNA was extracted from the cells using a miRNA extraction kit (mirVana miRNA Isolation Kit), and cDNA was synthesized using a ReverTra Ace qPCR RT Master Mix with gDNA Remover, and then it was used as a template DNA to confirm the transcript expression level. In order to confirm the expression of ogt mRNA, primer pairs of ogt-qper1 and ogt-qper2 were used, and qPCR reactions were performed using primer pairs of gapdh-qper1 and gapdh-qper2 as a reference gene, respectively. It was confirmed whether or not the gene sequence was amplified at the transcript level. The sequences of each primer pair are shown in Table 3 below.
As shown in
As a result, it can be seen that the Gentiana trillora Pallas extract has an effect of improving insulin sensitivity and an effect of treating diseases related to insulin resistance by significantly reducing OGT, which acts to increase ITIH1.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2020-0109373 | Aug 2020 | KR | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/KR2021/011530 | 8/27/2021 | WO |
